Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Cardiomyopathies are a diverse group of cardiac disorders with distinct phenotypes, depending on the proteins and pathways affected. A substantial proportion of cardiomyopathies are inherited and those will be the focus of this review article. With the wide application of high-throughput sequencing in the practice of clinical genetics, the roles of novel genes in cardiomyopathies are recognised. Here, we focus on a subgroup of cardiomyopathy genes [TTN, FHL1, CSRP3, FLNC and PLN, coding for Titin, Four and a Half LIM domain 1, Muscle LIM Protein, Filamin C and Phospholamban, respectively], which, despite their diverse biological functions, all have important signalling functions in the heart, suggesting that disturbances in signalling networks can contribute to cardiomyopathies.

Original publication

DOI

10.1007/s10974-017-9487-3

Type

Journal article

Journal

J Muscle Res Cell Motil

Publication Date

08/2017

Volume

38

Pages

303 - 316

Keywords

Cardiomyopathies, Genetic pathogenic variant, Heart, Mouse models, Mutation, Signalling, Titin, Variant of unknown significance, Animals, Cardiomyopathies, Humans, Intracellular Signaling Peptides and Proteins, Muscle Proteins, Signal Transduction